Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Mangoceuticals, Inc. ( (MGRX) ).
On February 23, 2026, Mangoceuticals reported new data on its patented antiviral compound MGX-0024, aimed at reducing respiratory disease in commercial poultry and improving protection against highly pathogenic avian influenza H5N1. The compound, a GRAS-classified blend of polyphenols and zinc delivered via drinking water, is protected by patents in major markets and reflects the company’s move into non-antibiotic, non-vaccine biosecurity tools for poultry producers.
In three commercial field trials in Tamil Nadu, India, involving about 29,000 broiler chickens treated with MGX-0024 from day 14 to market age without other antivirals or antibiotics, the company reported zero mortality from respiratory pathogens, versus an expected respiratory-related death rate of roughly 50% based on historical and neighboring flocks. These results reinforced earlier May 2025 trials in 8,000–10,000 birds, though diagnostic confirmation relied primarily on clinical observations and farm records rather than uniform lab testing.
A controlled H5N1 challenge study at India’s ICAR-NIHSAD BSL-3 facility found that birds pre-treated with MGX-0024 for 48 hours showed up to a 60% reduction in mortality versus untreated controls and a longer time to death, with survivors displaying only intermittent, low-level viral shedding and remaining seronegative at day 14. While the sample size was small, the study provides preliminary evidence of prophylactic benefit against H5N1 and suggests MGX-0024 may offer early interference with infection establishment.
Mangoceuticals and partner IntraMont Technologies are using these results to drive regulatory engagement and commercial discussions in markets including India, the United States, Australia, the UK, and Canada, citing strong interest from distributors, farms, and agencies amid global efforts to cut antibiotic use in poultry. The company is scaling production, planning further multi-farm studies, and pursuing grant funding, although it emphasizes that the findings are preliminary, not yet independently validated at scale, and remain subject to regulatory review and variable field performance.
More about Mangoceuticals, Inc.
Mangoceuticals, Inc., listed on Nasdaq as MGRX, operates in the health and wellness sector, primarily developing and marketing men’s health products through its MangoRx telemedicine platform. The company currently offers pharmaceutical-based treatments for erectile dysfunction, hair growth, hormone replacement therapies, and weight management, with prescriptions reviewed by licensed medical providers and filled via a partner compounding pharmacy.
Alongside its consumer telehealth franchise, Mangoceuticals is expanding into animal health through proprietary wellness solutions, including the antiviral compound MGX-0024 for poultry. This diversification positions the company at the intersection of human telemedicine and veterinary biosecurity, targeting markets such as India and other key poultry-producing regions.
Average Trading Volume: 748,148
Technical Sentiment Signal: Sell
Current Market Cap: $5.86M
See more insights into MGRX stock on TipRanks’ Stock Analysis page.